Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials

Infections in patients diagnosed with multiple sclerosis: A multi-database study

(2020) R. Persson et al.   Multiple Sclerosis and Related Disorders

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis

(2019) Johann Sellner et al.   AUTOIMMUNITY REVIEWS

Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis

(2019) Claudia Volpi et al.   Expert Opinion on Drug Discovery

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta‐analysis

(2019) Ting Yang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis

(2018) Daniel Kantor et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

(2018) Yara Dadalti Fragoso et al.   Multiple Sclerosis and Related Disorders

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

(2018) Tanuja Chitnis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways

(2018) Alan Baer et al.   Scientific Reports

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

(2017) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY

Infectious Complications of Novel Multiple Sclerosis Therapies

(2017) S. N. Levin et al.   Current Infectious Disease Reports

Safety concerns and risk management of multiple sclerosis therapies

(2016) P. Soelberg Sorensen   ACTA NEUROLOGICA SCANDINAVICA

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature

(2016) Elena Grebenciucova et al.   Multiple Sclerosis and Related Disorders

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

(2015) Samuel F. Hunter et al.   CNS DRUGS

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

(2015) L. Kappos et al.   NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

VZV encephalitis that developed in an immunized patient during fingolimod therapy

(2014) N. P. Issa et al.   NEUROLOGY

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Edward Fox et al.   Multiple Sclerosis and Related Disorders

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

(2013) Jeffrey A. Cohen et al.   JOURNAL OF NEUROLOGY

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

(2012) T Saida et al.   Multiple Sclerosis Journal

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

(2009) Alessandro Liberati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY